|
gptkbp:instanceOf
|
gptkb:drug
sulfonylurea
antidiabetic medication
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A10BB12
|
|
gptkbp:availableOn
|
generic
|
|
gptkbp:brand
|
gptkb:Amaryl
|
|
gptkbp:CASNumber
|
93479-97-1
|
|
gptkbp:chemicalFormula
|
C24H34N4O5S
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
hypersensitivity to sulfonylureas
|
|
gptkbp:discoveredBy
|
gptkb:Hoechst_AG
|
|
gptkbp:drugInteraction
|
gptkb:beer
gptkb:rifampin
gptkb:warfarin
gptkb:fluconazole
gptkb:NSAIDs
gptkb:gemfibrozil
gptkb:thiazide_diuretics
beta blockers
corticosteroids
ACE inhibitors
|
|
gptkbp:eliminationHalfLife
|
5-8 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Glimepiride
|
|
gptkbp:IUPACName
|
1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea
|
|
gptkbp:KEGGID
|
D00564
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
stimulates insulin release from pancreatic beta cells
|
|
gptkbp:MedlinePlusID
|
a696016
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
490.62 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1431
3476
3356
DB00222
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
nausea
dizziness
weight gain
allergic skin reactions
|
|
gptkbp:synonym
|
gptkb:Amaryl
Glimipiride
|
|
gptkbp:UNII
|
X9X8Y6A4BN
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Servier
gptkb:Servier_Pharmaceuticals
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|